Home    Back

Continuation of current haart (boosted protease inhibitor [pi] combination + 2 nrtis)    (DrugBank: -)

1 disease
IDDisease name (Link within this page)Number of trials
265Lipodystrophy1

265. Lipodystrophy    [ 109 clinical trials,   164 drugs,   (DrugBank: 59 drugs),   26 drug target genes,   94 drug target pathways]
Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 109 trial found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT00135356
(ClinicalTrials.gov)		July 200525/8/2005Study of Reyataz in HIV-infected Patients With Lipodystrophy SyndromeA Phase IV, Open-Label, Randomized, Multicenter Trial Assessing a Reyataz-Based Substitution Approach in the Management of Lipodystrophy Syndrome. Research Into Atazanavir in Lipodystrophy (The REAL Study)HIV-Associated Lipodystrophy SyndromeDrug: Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs);Drug: continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)Bristol-Myers SquibbNULLCompleted18 YearsN/AAll219Phase 4United States;Canada;France;Germany;Italy;Mexico;Poland;Spain;United Kingdom;Netherlands